Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by EntryPoint Capital LLC

EntryPoint Capital LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 67.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,503 shares of the company’s stock after purchasing an additional 605 shares during the quarter. EntryPoint Capital LLC’s holdings in Medpace were worth $499,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new position in shares of Medpace in the 4th quarter valued at $30,000. SBI Securities Co. Ltd. purchased a new position in shares of Medpace during the fourth quarter worth about $31,000. Stone House Investment Management LLC acquired a new stake in shares of Medpace during the third quarter worth about $33,000. Jones Financial Companies Lllp lifted its holdings in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after purchasing an additional 110 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its position in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Down 1.8 %

NASDAQ MEDP opened at $324.51 on Wednesday. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The firm has a 50-day moving average price of $337.16 and a 200 day moving average price of $339.57. The stock has a market capitalization of $9.89 billion, a P/E ratio of 25.69, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on MEDP. Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday. They issued a “market perform” rating and a $330.00 price target for the company. Finally, Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Medpace has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.